Royce Syracuse, MD
Ophthalmology · Charlotte, NCNPI 1134119605
Payments from drug & device makers
Across 157 payments — averaging $61.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Notal Vision, Inc.$1K
- AbbVie$1K
- US Retina LLC$814
- Bausch & Lomb Americas Inc.$580
- Johnson & Johnson Surgical Vision, Inc.$567
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$1,34314%
- Travel & lodging$120%
- Food & beverage$7,40877%
- Education$491%
- Ownership interest$8148%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 36 | $1,843 |
| Notal Vision, Inc. | 7 | $1,385 |
| AbbVie(2 entities) | 29 | $1,116 |
| US Retina LLC | 12 | $814 |
| Bausch & Lomb Americas Inc. | 7 | $580 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $567 |
| Aerie Pharmaceuticals, Inc. | 10 | $508 |
| Amgen(2 entities) | 3 | $371 |
| Kala Pharmaceuticals, Inc. | 5 | $329 |
| Glaukos Corporation | 4 | $236 |
| Bayer | 2 | $221 |
| Novo Nordisk | 2 | $220 |
| NEW World Medical,inc. | 1 | $219 |
| Tarsus Pharmaceuticals, Inc. | 6 | $189 |
| Astellas Pharma US Inc | 5 | $128 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Rxsight Inc | 1 | $111 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $105 |
| Biotissue Holdings Inc. | 1 | $99 |
| Lilly USA, LLC | 1 | $97 |
| Oyster Point Pharma, Inc. | 4 | $96 |
| Sun Pharmaceutical Industries Inc. | 3 | $70 |
| Rayner Intraocular Lenses Limited | 2 | $51 |
| Harrow Eye, LLC | 1 | $31 |
| Thea Pharma Inc. | 1 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $26 |
| Novartis | 1 | $24 |
| Dompe US, Inc. | 1 | $19 |
| Eyepoint US, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$760
- TEPEZZA$371
- Tecnis IOL$355
- INVELTYS$263
- enVista MX60 IOL$260
- MIEBO$249
- DURYSTA$244
- Rhopressa$222
- Rocklatan$222
- Ahmed Glaucoma Valve$219
- Kahook Dual Blade$219
- Clareon PanOptix Pro$145
- XIIDRA$145
- NUZYRA$125
- RYBELSUS$123
- Kerendia$122
- IACCESS$119
- iStent inject W$119
- Tecnis Simplicity$118
- XEN$113
How this compares
$9,626 in reported general payments places this provider in the 80th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 133 | $158,885 |
| XiidraLifitegrast | 43 | $56,276 |
| RocklatanNetarsudil Mesylat/Latanoprost | 66 | $35,887 |
| LumiganBimatoprost | 52 | $28,982 |
| RhopressaNetarsudil Mesylate | 27 | $18,541 |
| VyzultaLatanoprostene Bunod | 31 | $13,757 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $8,568 |
| Cyclosporine | 14 | $8,318 |
| Latanoprost | 566 | $7,408 |
| Alphagan PBrimonidine Tartrate | 21 | $6,188 |
| Travoprost | 43 | $6,140 |
| Brimonidine Tartrate | 123 | $3,959 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $3,708 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,702 |
| Prednisolone Acetate | 84 | $2,653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,116 | $202,623226 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $580 | $70,03374 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $508 | $54,42893 claims |
| AlconSimbrinza | $1,843 | $2,70213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Charlotte
- Andrew AntoszykCharlotte$4M
- Omar PunjabiCharlotte$413K
- Thomas MundorfCharlotte$288K
- John AllenCharlotte$122K
- Sheila Garcia-SantanaCharlotte$60K
- David BrowningCharlotte$59K
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Majda HadziahmetovicDurham$2.4M
- Preeya GuptaRaleigh$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.